$CRDF
Cardiff Oncology, Inc.

2022 Q4 Form 10-Q Financial Statement

#000162828022028164 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $128.0K $93.00K
YoY Change -3.76% 8.14%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.078M $3.077M
YoY Change -19.74% 5.02%
% of Gross Profit
Research & Development $6.442M $6.009M
YoY Change 10.61% 44.66%
% of Gross Profit
Depreciation & Amortization $86.00K $81.00K
YoY Change -23.89% -26.36%
% of Gross Profit
Operating Expenses $9.520M $9.086M
YoY Change -1.44% 28.26%
Operating Profit -$8.993M
YoY Change 28.51%
Interest Expense $740.0K $458.0K
YoY Change 780.95% 458.54%
% of Operating Profit
Other Income/Expense, Net -$45.00K $422.0K
YoY Change 13966.67%
Pretax Income -$8.697M -$8.571M
YoY Change -7.89% 23.98%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.703M -$8.571M
YoY Change -7.83% 23.98%
Net Earnings / Revenue -6799.22% -9216.13%
Basic Earnings Per Share -$0.20
Diluted Earnings Per Share -$0.20 -$0.20
COMMON SHARES
Basic Shares Outstanding 44.68M shares 43.33M shares
Diluted Shares Outstanding 43.33M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $100.3M $107.2M
YoY Change -6.75% -20.02%
Cash & Equivalents $16.35M $18.72M
Short-Term Investments $83.92M $88.50M
Other Short-Term Assets $5.246M $4.802M
YoY Change 9.96% 44.33%
Inventory
Prepaid Expenses $5.246M $4.802M
Receivables $771.0K $650.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $111.3M $119.8M
YoY Change -23.84% -13.08%
LONG-TERM ASSETS
Property, Plant & Equipment $1.269M $1.304M
YoY Change 232.2% 240.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.387M $184.0K
YoY Change 480.33% 28.67%
Total Long-Term Assets $4.907M $3.876M
YoY Change 43.61% 9.4%
TOTAL ASSETS
Total Short-Term Assets $111.3M $119.8M
Total Long-Term Assets $4.907M $3.876M
Total Assets $116.2M $123.6M
YoY Change -22.3% -12.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.956M $1.425M
YoY Change 35.93% 259.85%
Accrued Expenses $5.177M $6.138M
YoY Change 14.36% 53.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.808M $8.245M
YoY Change 19.04% 63.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.040M $2.174M
YoY Change 7146.67%
Total Long-Term Liabilities $2.040M $2.174M
YoY Change 7146.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.808M $8.245M
Total Long-Term Liabilities $2.040M $2.174M
Total Liabilities $9.848M $10.42M
YoY Change 7.9% 34.13%
SHAREHOLDERS EQUITY
Retained Earnings -$298.1M -$289.8M
YoY Change 14.74% 15.77%
Common Stock $4.000K $4.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $106.3M $113.2M
YoY Change
Total Liabilities & Shareholders Equity $116.2M $123.6M
YoY Change -22.3% -12.51%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$8.703M -$8.571M
YoY Change -7.83% 23.98%
Depreciation, Depletion And Amortization $86.00K $81.00K
YoY Change -23.89% -26.36%
Cash From Operating Activities -$9.390M -$7.486M
YoY Change 27.06% 36.98%
INVESTING ACTIVITIES
Capital Expenditures $75.00K -$448.0K
YoY Change -170.09% 357.14%
Acquisitions
YoY Change
Other Investing Activities $7.095M $5.611M
YoY Change -181.67% -31.13%
Cash From Investing Activities $7.020M $5.163M
YoY Change -179.83% -35.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 75.00K
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -9.390M -7.486M
Cash From Investing Activities 7.020M 5.163M
Cash From Financing Activities 0.000 75.00K
Net Change In Cash -2.370M -2.248M
YoY Change 93.94% -187.0%
FREE CASH FLOW
Cash From Operating Activities -$9.390M -$7.486M
Capital Expenditures $75.00K -$448.0K
Free Cash Flow -$9.465M -$7.038M
YoY Change 29.96% 31.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001213037
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35558
dei Entity Registrant Name
EntityRegistrantName
CARDIFF ONCOLOGY, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-2004382
dei Entity Address Address Line1
EntityAddressAddressLine1
11055 Flintkote Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
952-7570
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
CRDF
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44677169 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18717000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11943000 usd
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
95586000 usd
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
128878000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
650000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
535000 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4802000 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4771000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
119755000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
146127000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1304000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
382000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
5150000 shares
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2388000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2796000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
184000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
239000 usd
CY2022Q3 us-gaap Assets
Assets
123631000 usd
CY2021Q4 us-gaap Assets
Assets
149544000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1425000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1439000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6138000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4527000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
674000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
551000 usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
8000 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
42000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8245000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6559000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2174000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2568000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
10419000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
9127000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
1000 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43335000 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43335000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41964000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41964000 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
4000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
403822000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
400503000 usd
CY2022Q3 crdf Service Receivable
ServiceReceivable
0 usd
CY2021Q4 crdf Service Receivable
ServiceReceivable
139000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-779000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-142000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-289835000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-259810000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
113212000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
140417000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
123631000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
149544000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
93000 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
86000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
258000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
226000 usd
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6009000 usd
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4154000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
20665000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
11552000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3077000 usd
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2930000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10103000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8003000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
9086000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
7084000 usd
us-gaap Operating Expenses
OperatingExpenses
30768000 usd
us-gaap Operating Expenses
OperatingExpenses
19555000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8993000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6998000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-30510000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-19329000 usd
CY2022Q3 us-gaap Interest Income Operating
InterestIncomeOperating
458000 usd
CY2021Q3 us-gaap Interest Income Operating
InterestIncomeOperating
70000 usd
us-gaap Interest Income Operating
InterestIncomeOperating
841000 usd
us-gaap Interest Income Operating
InterestIncomeOperating
185000 usd
CY2022Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0 usd
CY2021Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
12000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
280000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-36000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-338000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
422000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
85000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
503000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
480000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8571000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6913000 usd
us-gaap Net Income Loss
NetIncomeLoss
-30007000 usd
us-gaap Net Income Loss
NetIncomeLoss
-18849000 usd
CY2022Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6000 usd
CY2021Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6000 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
18000 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
18000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8577000 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6919000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30025000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18867000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43333000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43333000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39552000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39552000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43291000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43291000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38501000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38501000 shares
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8571000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6913000 usd
us-gaap Net Income Loss
NetIncomeLoss
-30007000 usd
us-gaap Net Income Loss
NetIncomeLoss
-18849000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
203000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
26000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-637000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
16000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8368000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6887000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30644000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18833000 usd
CY2022Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6000 usd
CY2021Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6000 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
18000 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
18000 usd
CY2022Q3 crdf Comprehensive Income Loss Available To Common Stockholders Basic
ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
-8374000 usd
CY2021Q3 crdf Comprehensive Income Loss Available To Common Stockholders Basic
ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
-6893000 usd
crdf Comprehensive Income Loss Available To Common Stockholders Basic
ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
-30662000 usd
crdf Comprehensive Income Loss Available To Common Stockholders Basic
ComprehensiveIncomeLossAvailableToCommonStockholdersBasic
-18851000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
140417000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1152000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-606000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
-1000 usd
CY2022Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000 usd
CY2022Q1 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
139000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-10993000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
130102000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1055000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-234000 usd
CY2022Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10443000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
120474000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1037000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
75000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
203000 usd
CY2022Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8571000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
113212000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
128158000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
268000 usd
CY2021Q1 crdf Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1263000 usd
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-67000 usd
CY2021Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000 usd
CY2021Q1 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
380000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5179000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
124817000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1036000 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19225000 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
57000 usd
CY2021Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000 usd
CY2021Q2 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
546000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6757000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
138918000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
940000 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
26000 usd
CY2021Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6000 usd
CY2021Q3 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
579000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6913000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
133544000 usd
CY2021Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
800000 usd
us-gaap Net Income Loss
NetIncomeLoss
-30007000 usd
us-gaap Net Income Loss
NetIncomeLoss
-18849000 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-1000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
150000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
338000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3244000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2244000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-672000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1160000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
280000 usd
crdf Release Of Clinical Trial Funding Commitment For Services Received
ReleaseOfClinicalTrialFundingCommitmentForServicesReceived
139000 usd
crdf Release Of Clinical Trial Funding Commitment For Services Received
ReleaseOfClinicalTrialFundingCommitmentForServicesReceived
1505000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-55000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-261000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
115000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
74000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-4000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
741000 usd
crdf Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-408000 usd
crdf Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-386000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1325000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-830000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-271000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-645000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-34000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-126000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24430000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15650000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
931000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
98000 usd
us-gaap Proceeds From Insurance Settlement Investing Activities
ProceedsFromInsuranceSettlementInvestingActivities
114000 usd
us-gaap Proceeds From Insurance Settlement Investing Activities
ProceedsFromInsuranceSettlementInvestingActivities
0 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
61229000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
15101000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
80428000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
146632000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
51145000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
8975000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31129000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-122654000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
776000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19225000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
75000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1263000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20488000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6774000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-117816000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11943000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
130981000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18717000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13165000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
1000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
1000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
255000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
crdf Preferred Stock Dividend Accrued
PreferredStockDividendAccrued
18000 usd
crdf Preferred Stock Dividend Accrued
PreferredStockDividendAccrued
18000 usd
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
114300000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10934858 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10742475 shares
CY2022Q3 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
89216000 usd
CY2022Q3 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
11000 usd
CY2022Q3 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
728000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
88499000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
7148000 usd
CY2022Q3 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
4000 usd
CY2022Q3 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
65000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
7087000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
96364000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
15000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
793000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
95586000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
95643000 usd
CY2021Q4 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
6000 usd
CY2021Q4 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
65000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
95584000 usd
CY2021Q4 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
33377000 usd
CY2021Q4 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
1000 usd
CY2021Q4 crdf Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
84000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
33294000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
129020000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
149000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
128878000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
2590000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
28000 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4633000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3823000 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3329000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3441000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1304000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
382000 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1609000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1435000 usd
CY2022Q3 crdf Accrued Preferred Stock Dividend
AccruedPreferredStockDividend
432000 usd
CY2021Q4 crdf Accrued Preferred Stock Dividend
AccruedPreferredStockDividend
414000 usd
CY2022Q3 crdf Accrued Clinical Trial
AccruedClinicalTrial
2132000 usd
CY2021Q4 crdf Accrued Clinical Trial
AccruedClinicalTrial
1639000 usd
CY2022Q3 crdf Accrued Research Agreements
AccruedResearchAgreements
1125000 usd
CY2021Q4 crdf Accrued Research Agreements
AccruedResearchAgreements
726000 usd
CY2022Q3 crdf Accrued Director Fees
AccruedDirectorFees
125000 usd
CY2021Q4 crdf Accrued Director Fees
AccruedDirectorFees
141000 usd
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
29000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
63000 usd
CY2022Q3 crdf Patent License And Other Fees Payable
PatentLicenseAndOtherFeesPayable
122000 usd
CY2021Q4 crdf Patent License And Other Fees Payable
PatentLicenseAndOtherFeesPayable
43000 usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
564000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
66000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6138000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4527000 usd
crdf Lessee Operating Lease Area Of Lease
LesseeOperatingLeaseAreaOfLease
12300 sqft
crdf Lessee Operating Lease Monthly Rent Payment
LesseeOperatingLeaseMonthlyRentPayment
60000 usd
crdf Lessee Operating Lease Annual Rent Increase Percentage
LesseeOperatingLeaseAnnualRentIncreasePercentage
0.03
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
188000 usd
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
281000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
568000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
468000 usd
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
0 usd
CY2021Q3 us-gaap Sublease Income
SubleaseIncome
101000 usd
us-gaap Sublease Income
SubleaseIncome
0 usd
us-gaap Sublease Income
SubleaseIncome
303000 usd
CY2022Q3 us-gaap Lease Cost
LeaseCost
188000 usd
CY2021Q3 us-gaap Lease Cost
LeaseCost
180000 usd
us-gaap Lease Cost
LeaseCost
568000 usd
us-gaap Lease Cost
LeaseCost
165000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2388000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2796000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
674000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
551000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2174000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2568000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2848000 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3119000 usd
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y6M
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y2M12D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.070
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.070
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
180000 usd
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
243000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
431000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
726000 usd
CY2022Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2021Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3061000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3061000 usd
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
3150000 shares
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
120000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
737000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
754000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
775000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
796000 usd
CY2022Q3 crdf Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
137000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3319000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
471000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2848000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1037000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
940000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3244000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2244000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4000000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1200000 usd
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
3150000 shares
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4490159 shares
CY2021Q4 crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
5.80
crdf Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights
ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
P3Y
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4490159 shares
CY2022Q3 crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
5.80
crdf Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights
ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
P2Y2M12D

Files In Submission

Name View Source Status
0001628280-22-028164-index-headers.html Edgar Link pending
0001628280-22-028164-index.html Edgar Link pending
0001628280-22-028164.txt Edgar Link pending
0001628280-22-028164-xbrl.zip Edgar Link pending
crdf-093022exhibit311.htm Edgar Link pending
crdf-093022exhibit312.htm Edgar Link pending
crdf-093022exhibit321.htm Edgar Link pending
crdf-093022exhibit322.htm Edgar Link pending
crdf-20220930.htm Edgar Link pending
crdf-20220930.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
crdf-20220930_cal.xml Edgar Link unprocessable
crdf-20220930_def.xml Edgar Link unprocessable
crdf-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
crdf-20220930_lab.xml Edgar Link unprocessable
crdf-20220930_htm.xml Edgar Link completed